Lulin Ma
Peking University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Lulin Ma.
Asian Journal of Urology | 2014
Rui Chen; Shancheng Ren; Ming Kwong Yiu; Ng Chi Fai; Wai Sam Cheng; Lap Hong Ian; Seiji Naito; Elijah Kehinde; Ali Riza Kural; Jason Yichun Chiu; Rainy Umbas; Qiang Wei; Xiaolei Shi; Liqun Zhou; Jian Huang; Yiran Huang; Liping Xie; Lulin Ma; Changjun Yin; Danfeng Xu; Kexin Xu; Zhangqun Ye; Chunxiao Liu; Dingwei Ye; Xin Gao; Qiang Fu; Jianquan Hou; Jianlin Yuan; Dalin He; Tiejun Pan
The incidence of prostate cancer (PCa) within Asian population used to be much lower than in the Western population; however, in recent years the incidence and mortality rate of PCa in some Asian countries have grown rapidly. This collaborative report summarized the latest epidemiology information, risk factors, and racial differences in PCa diagnosis, current status and new trends in surgery management and novel agents for castration-resistant prostate cancer. We believe such information would be helpful in clinical decision making for urologists and oncologists, health-care ministries and medical researchers.
PLOS ONE | 2015
Rui Chen; Yiran Huang; Xiaobing Cai; Liping Xie; Dalin He; Liqun Zhou; Chuanliang Xu; Xu Gao; Shancheng Ren; Fubo Wang; Lulin Ma; Qiang Wei; Changjun Yin; Ye Tian; Zhongquan Sun; Qiang Fu; Qiang Ding; Jun-Hua Zheng; Zhangqun Ye; Dingwei Ye; Danfeng Xu; Jianquan Hou; Kexin Xu; Jianlin Yuan; Xin Gao; Chunxiao Liu; Tiejun Pan; Yinghao Sun
Objective The influence of age on the performance of percent free prostate-specific antigen (%fPSA) in diagnosing prostate cancer (PCa) in East Asians is controversial. We tested the diagnostic performance of %fPSA in a multi-center biopsy cohort in China and identified the proper age-specific cutoff values to avoid unnecessary biopsies. Methods Consecutive patients with a prostate-specific antigen (PSA) level of 4.0–10.0 ng/ml or 10.1–20.0 ng/ml who underwent transrectal ultrasound-guided or transperineal prostate biopsy were enrolled from 22 Chinese medical centers from Jan 1, 2010 to Dec 31, 2013. The diagnostic accuracy of PSA and %fPSA was determined using the area under the receiver operating characteristic (ROC) curve (AUC). Age-specific cutoff values were calculated using ROC curve analysis. Results The median %fPSA was much lower in younger patients compared with older patients with a PSA level of 4.0–10.0 ng/ml or 10.1–20.0 ng/ml. The AUC of %fPSA was higher than PSA only in older patients. In patients aged 50 to 59 years, %fPSA failed to improve the diagnosis compared with PSA in these two PSA ranges. Age-specific cutoff values were 24%, 27% and 32% for patients aged 60–69, 70–79 and ≥80 years, respectively, to reduce unnecessary biopsies in men with PSA levels of 4.0–10.0 ng/ml to detect 90% of all PCa. Conclusions The effectiveness of %fPSA is correlated with age in the Chinese population. Age-specific cutoff values would help avoid unnecessary biopsies in the Chinese population.
International Journal of Oral and Maxillofacial Surgery | 2015
S. Ren; Lulin Ma; X. Zhou; Zhi-Peng Sun
The aim of this study was to visualize bony defects of the palate and vomer in submucous cleft palate patients (SMCP) by three-dimensional (3D) computed tomography (CT) reconstruction and to classify the range of bony defects. Forty-eight consecutive non-operated SMCP patients were included. Diagnosis was based on the presence of at least one of three classical signs of SMCP: bifid uvula, a translucent zone in the midline of the soft palate, and a palpable V notch on the posterior border of the bony palate. Patients were imaged using spiral CT. 3D reconstruction models were created of the palate and vomer. The sagittal extent of the bony cleft in SMCP was classified into four types: type I, no V-shaped hard palate cleft (8.3%); type II, cleft involving the partial palate (43.8%); type III, cleft involving the complete palate and extending to the incisive foramen (43.8%); type IV, cleft involving the complete palate and the alveolar bone (4.2%). The extent of the vomer defect was classified into three types: type A, vomer completely fused with the palate (8.3%); type B, vomer partially fused with the palate (43.8%); type C, vomer not fused with the palate up to the incisive foramen (47.9%). Significant variability in hard palate defects in SMCP is the rule rather than the exception. The association of velopharyngeal insufficiency with anatomical malformations may be complex.
Asian Journal of Urology | 2015
Kaiwen Li; Tianxin Lin; Wei Xue; Xin Mu; Enci Xu; Xu Yang; Fubao Chen; Guangyong Li; Lulin Ma; Guoliang Wang; Chaozhao Liang; Haoqiang Shi; Ming Li; Mao Tang; Xueyi Xue; Yi-Song Lv; Yaoliang Deng; Chengyang Li; Zhiwen Chen; Xiaozhou Zhou; Fengshuo Jin; Xudong Liu; Jinxin Wei; Lei Shi; Xin Gou; Weiyang He; Liqun Zhou; Lin Cai; Baiye Jin; Guanghou Fu
Objective To investigate current status of diagnosis and treatment of bladder cancer in China. Methods A database was generated by Chinese Bladder Cancer Consortium (CBCC). From January 2007 to December 2012, 14,260 cases from 44 CBCC centers were included. Data of diagnosis, treatment and pathology were collected. Results The average age was 63.5 year-old and most patients were male (84.3%). The most common histologic types were urothelial carcinoma (91.4%), adenocarcinoma (1.8%), and squamous carcinoma (1.9%). According to 1973 and 2004 WHO grading system, 42.0%, 41.0%, and 17.0% of patients were grade 1, 2, and 3, and 16.0%, 48.7%, and 35.3% of patients were papillary urothelial neoplasms of low malignant potential, low, and high grade, respectively. Non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC) were 25.2% and 74.1%, respectively (0.8% not clear). Carcinoma in situ was only 2.4%. Most patients were diagnosed by white-light cystoscopy with biopsy (74.3%). Fluorescence and narrow band imaging cystoscopy had additional detection rate of 1.0% and 4.0%, respectively. Diagnostic transurethral resection (TUR) provided detection rate of 16.9%. Most NMIBCs were treated with TUR (89.2%). After initial TUR, 2.6% accepted second TUR, and 45.7%, 69.9%, and 58.7% accepted immediate, induced, and maintenance chemotherapy instillation, respectively. Most MIBCs were treated with radical cystectomy (RC, 59.7%). Laparoscopic RCs were 35.1%, while open RC 63.4%. Extended and standard pelvic lymph node dissection were 7% and 66%, respectively. Three most common urinary diversions were orthotopic neobladder (44%), ileal conduit (31%), and ureterocutaneostomy (23%). Only 2.3% of patients accepted neo-adjuvant chemotherapy and only 18% of T3 and T4 patients accepted adjuvant chemotherapy. Conclusion Disease characteristics are similar to international reports, while differences of diagnosis and treatment exist. This study can provide evidences for revisions of the guideline on bladder cancer in China.
The Journal of Urology | 2017
Rui Chen; Daniel D. Sjoberg; Yiran Huang; Liping Xie; Zhou Lq; Dalin He; Andrew J. Vickers; Yinghao Sun; Qiang Ding; Qiang Wei; Pengfei Shao; Ye Tian; Zhongquan Sun; Qiang Fu; Lulin Ma; Jun-Hua Zheng; Zhangqun Ye; Dingwei Ye; Danfeng Xu; Jianquan Hou; Kexin Xu; Jianlin Yuan; Xin Gao; Chunxiao Liu; Tiejun Pan; Xu Gao; Shancheng Ren; Chuanliang Xu; Monique J. Roobol; Jonas Hugosson
Purpose: We determined the characteristics of Chinese men undergoing initial prostate biopsy and evaluated the relationship between prostate specific antigen levels and prostate cancer/high grade prostate cancer detection in a large Chinese multicenter cohort. Materials and Methods: This retrospective study included 13,904 urology outpatients who had undergone biopsy for the indications of prostate specific antigen greater than 4.0 ng/ml or prostate specific antigen less than 4.0 ng/ml but with abnormal digital rectal examination results. The prostate specific antigen measurements were performed in accordance with the standard procedures at the respective institutions. The type of assay used was documented and recalibrated to the WHO standard. Results: The incidence of prostate cancer and high grade prostate cancer was lower in the Chinese cohort than the Western cohorts at any given prostate specific antigen level. Around 25% of patients with a prostate specific antigen of 4.0 to 10.0 ng/ml were found to have prostate cancer compared to approximately 40% in U.S. clinical practice. Moreover, the risk curves were generally flatter than those of the Western cohorts, that is risk did not increase as rapidly with higher prostate specific antigen. Conclusions: The relationship between prostate specific antigen and prostate cancer risk differs importantly between Chinese and Western populations, with an overall lower risk in the Chinese cohort. Further research should explore whether environmental or genetic differences explain these findings or whether they result from unmeasured differences in screening or benign prostate disease. Caution is required for the implementation of prostate cancer clinical decision rules or prediction models for men in China or other Asian countries with similar genetic and environmental backgrounds.
BMJ Open | 2016
Yuke Chen; Wei Yu; Liqun Zhou; Shiliang Wu; Yang Yang; Jianye Wang; Ye Tian; Dalin He; Yong Xu; Jian Huang; Xiaofeng Wang; Xin Gao; Hanzhong Li; Lulin Ma; Ning Zhang; Shengtian Zhao; Xunbo Jin
Objectives This study assessed the effect of diet habits on lower urinary tract symptoms (LUTS) and sexual function in Chinese men with LUTS/benign prostatic hypertrophy (LUTS/BPH). Setting Multicentre study conducted between July 2013 and December 2013 in 11 hospitals in 3 geographic regions in China. Participants Overall, participants with LUTS/BPH accounted for 61.4% (2584/4208) of the respondents, whose data were processed in the following statistical analysis. Primary and secondary outcome measures LUTS and sexual function were assessed based on the International Prostate Symptom Score (IPSS) and the International Index of Erectile Function 5 (IIEF-5) score. Prostate volume (PV) was determined by ultrasound. Results A total of 4208 participants met the inclusion criteria. The average age of the whole participants was 65.8±7.7u2005years. Overall, participants with LUTS/BPH accounted for 61.4% (2584/4208) of the respondents, whose data were processed in the following statistical analysis. Generally, prostate enlargement was greatest in south China. LUTS and male sexual dysfunction (MSD) were most severe in northwest China. Based on multivariable analysis, PV enlarged as the age (p<0.001), body mass index (BMI; p<0.001) and vegetable intake (p<0.001) increased. Age (p<0.001) and BMI (p<0.05) independently increased the IPSS. A higher level of education (p<0.001) and more frequent meat, fish and egg intake (p<0.05) decreased the IPSS. Age (p<0.001), BMI (p<0.001), low education level (p<0.05), vegetable intake (p=0.001), and milk and dairy product intake (p=0.001) decreased the IIEF-5 score. Conclusions In addition to factors including age, obesity and level of education, dietary habits and geographic difference might also play an important role in the variation of PV, LUTS and MSD for Chinese men with LUTS/BPH.
Asian Journal of Urology | 2015
Rui Chen; Liping Xie; Xiaobing Cai; Yiran Huang; Liqun Zhou; Lulin Ma; Xu Gao; Chuanliang Xu; Shancheng Ren; Pengfei Shao; Danfeng Xu; Kexin Xu; Zhangqun Ye; Chunxiao Liu; Dingwei Ye; Li Lu; Qiang Fu; Jianquan Hou; Jianlin Yuan; Dalin He; Tie Zhou; Fubo Wang; Biming He; Yinghao Sun
Objective To test the diagnostic performance of percent free prostate-specific antigen (%fPSA) in predicting any prostate cancer (PCa) and high-grade prostate cancer (HGPCa) in a retrospective multi-center biopsy cohort with a PSA level of 4.0–10.0 ng/mL in China. Methods Consecutive patients with a PSA of 4.0–10.0 ng/mL who underwent transrectal ultrasound-guided biopsy were enrolled at 16 Chinese medical centers from January 1st, 2010 to December 31st, 2013. Total and free serum PSA determinations were performed using three types of electro-chemiluminescence immunoassays recalibrated to the World Health Organization (WHO) standard. The diagnostic accuracy of PSA, %fPSA, and %fPSA in combination with PSA (%fPSA + PSA) was determined using the area under the receiver operating characteristic (ROC) curve (AUC). Results A total of 2310 consecutive men with PSA levels between 4.0 and 10.0 ng/mL were included, and the detection rate of PCa was 25.1%. The AUC of %fPSA and %fPSA + PSA in predicting any PCa was superior to PSA alone in men aged ≥60 years (0.623 vs. 0.534, p < 0.0001) but not in men aged 40–59 years (0.517 vs. 0.518, p = 0.939). Similar result was yield in predicting HGPCa. Conclusion In a clinical setting of Chinese men with 4.0–10.0 ng/mL PSA undergoing initial prostate biopsy, adding %fPSA to PSA can moderately improve the diagnostic accuracy for any PCa and HGPCa compared with PSA alone in patients ≥60 but not in patients aged 40–59 years.
BJUI | 2017
Jing Leng; Limin Liao; Ben Wan; Chuanjun Du; Wei Li; Keji Xie; Zhoujun Shen; Zhuoqun Xu; Shiliang Wu; Zujun Fang; Lulin Ma; Shaomei Han; Cornelia Feustel; Yong Yang; Helmut Madersbacher
To compare the efficacy and safety of the 30 mg extended release (ER) formulation of propiverine hydrochloride with the 4 mg ER formulation of tolterodine tartrate in patients with overactive bladder (OAB) in a non‐inferiority trial.
Asian Journal of Urology | 2018
Liqun Zhou; Kaiwei Yang; Xuesong Li; Yi Ding; Dawei Mu; Hanzhong Li; Yong Yan; Jinyi Li; Dongwen Wang; Wei Li; Yulong Cong; Jiangping Gao; Kewei Ma; Yajun Xiao; Sheng Zhang; Hongyi Jiang; Weilie Hu; Qiang Wei; Xunbo Jin; Zhichen Guan; Qingyong Liu; Danfeng Xu; Xin Gao; Yongguang Jiang; Weimin Gan; Guang Sun; Qing Wang; Yanhui Liu; Jianquan Hou; Liping Xie
Objective To evaluate the diagnostic value of fluorescence in situ hybridization (FISH) in bladder cancer. Methods We enrolled healthy volunteers and patients who were clinically suspected to have bladder cancer and conducted FISH tests and cytology examinations from August 2007 to December 2008. Receiver operating characteristic (ROC) curve analysis was performed and the area under curve (AUC) values were calculated for both the FISH and urine cytology tests. Results A cohort of 988 healthy volunteers was enrolled to establish a reference range for the normal population. A total of 4807 patients with hematuria were prospectively, randomly enrolled for the simultaneous analysis of urine cytology, FISH testing, and a final diagnosis as determined by the pathologic findings of a biopsy or a surgically-excised specimen. Overall, the sensitivity of FISH in detecting transitional-cell carcinoma was 82.7%, while that of cytology was 33.4% (p < 0.001). The sensitivity values of FISH for non-muscle invasive and muscle invasive bladder transitional-cell carcinoma were 81.7% and 89.6%, respectively (p = 0.004). The sensitivity values of FISH for low and high grade bladder cancer were 82.6% and 90.1%, respectively (p = 0.002). Conclusion FISH is significantly more sensitive than voided urine cytology for detecting bladder cancer in patients evaluated for gross hematuria at all cancer grades and stages. Higher sensitivity using FISH was obtained in high grade and muscle invasive tumors.
International Journal of Oral and Maxillofacial Surgery | 2017
Lulin Ma